Bristol-Myers Squibb
About
Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical leader with a strong portfolio of drugs in oncology, immunology, cardiovascular, and fibrosis, including blockbusters like Eliquis, Opdivo, and Revlimid. The company is actively building its next-generation pipeline through strategic acquisitions and internal R&D to offset upcoming patent expirations. BMY offers an attractive dividend yield and trades at a modest valuation relative to big pharma peers, making it appealing for income-focused investors.
Dividend Aristocrat Stocks
Bristol-Myers Squibb is a biopharmaceutical leader in oncology and immunology with a strong dividend growth track record, navigating patent cliffs with a robust acquisition-driven pipeline strategy.
Dividend Stocks
Bristol-Myers Squibb offers an attractive and above-average dividend yield for the pharmaceutical sector, supported by strong free cash flow generation from its established drug portfolio and a commitment to returning capital to shareholders.
Pharmaceutical Stocks
Bristol-Myers Squibb is a top-tier global pharmaceutical company with a diverse portfolio of blockbuster drugs spanning oncology, cardiovascular, immunology, and fibrosis, generating tens of billions in annual revenue.
Key Financials BMY
Price
$60.74
Change (1D)
+1.47%
Change (30D)
+12.61%
Change (60D)
+29.76%
Change (90D)
+34.56%
Change (180D)
+29.32%
Change (1Y)
+8.17%
Change (5Y)
+1.64%
P/E Ratio
28.65
EPS (TTM)
$2.12
52-Week Range
$42.52 — $63.33
50-Day MA
$55.16
Volume
10.82M
Data updated Feb 15 · Source: Twelve Data
